Cargando…

Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI

The appearance of malignant lesions in BRCA1 and BRCA2 mutation carriers (BRCA-MCs) on mammography and magnetic resonance imaging (MRI) was evaluated. Thus, 29 BRCA-MCs with breast cancer were retrospectively evaluated and the results compared with an age, tumor size and tumor type matched control g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Veltman, J., Mann, R., Kok, T., Obdeijn, I. M., Hoogerbrugge, N., Blickman, J. G., Boetes, C.
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2008
Materias:	Breast
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2292493/ https://www.ncbi.nlm.nih.gov/pubmed/18270717 http://dx.doi.org/10.1007/s00330-008-0851-y

Ejemplares similares

Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers
por: Lo Gullo, Roberto, et al.
Publicado: (2020)

Contrast-enhanced magnetic resonance imaging of the breast: the value of pharmacokinetic parameters derived from fast dynamic imaging during initial enhancement in classifying lesions
por: Veltman, J., et al.
Publicado: (2008)

Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status
por: Goodburn, Rosie, et al.
Publicado: (2023)

The supplemental value of mammographic screening over breast MRI alone in BRCA2 mutation carriers
por: Obdeijn, Inge-Marie, et al.
Publicado: (2020)

Bilateral Triple Negative Invasive Ductal Breast Carcinoma in a BRCA1 Mutation Carrier with Discrepant Pathologic Response to Neoadjuvant Chemotherapy
Publicado: (2020)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

MR-guided breast biopsy at 3T: diagnostic yield of large core needle biopsy compared with vacuum-assisted biopsy
por: Meeuwis, Carla, et al.
Publicado: (2011)

Prophylactic Mastectomy in BRCA1/2 Mutation Carriers and Women at Risk of Hereditary Breast Cancer: Long-Term Experiences at the Rotterdam Family Cancer Clinic
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2007)

Screening women at increased risk with MRI: Monday 3 October 2005, 08:45–10:45
por: Boetes, C, et al.
Publicado: (2005)

Finding all BRCA pathogenic mutation carriers: best practice models
por: Hoogerbrugge, Nicoline, et al.
Publicado: (2016)

Characteristics, Treatment, and Outcomes of Real-World Talazoparib-Treated Patients With Germline BRCA-Mutated Advanced HER2-Negative Breast Cancer
por: Savill, Kristin M Zimmerman, et al.
Publicado: (2023)

Correction: Clinicopathological and ultrasound characteristics of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ikejima, Kengo, et al.
Publicado: (2023)

Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Metcalfe, K, et al.
Publicado: (2011)

Screening BRCA1 and BRCA2 Mutation Carriers for Breast Cancer
por: Warner, Ellen
Publicado: (2018)

Variation in breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Rebbeck, Timothy R, et al.
Publicado: (2008)

Risks of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers
por: Ahmed, M, et al.
Publicado: (2010)

Breastfeeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2012)

Survival after bilateral risk-reducing mastectomy in healthy BRCA1 and BRCA2 mutation carriers
por: Heemskerk-Gerritsen, Bernadette A. M., et al.
Publicado: (2019)

Multifocal breast cancers are more prevalent in BRCA2 versus BRCA1 mutation carriers
por: McCrorie, Alan D, et al.
Publicado: (2020)

Clinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review
por: Bougie, O., et al.
Publicado: (2011)

Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers
por: Antoniou, Antonis C, et al.
Publicado: (2006)

Plasma osteoprotegerin and breast cancer risk in BRCA1 and BRCA2 mutation carriers
por: Odén, Lovisa, et al.
Publicado: (2016)

The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers
por: Iqbal, J, et al.
Publicado: (2012)

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers
por: Kotsopoulos, Joanne, et al.
Publicado: (2005)

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial
por: Hurvitz, Sara A., et al.
Publicado: (2019)

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers
por: Pataky, Reka, et al.
Publicado: (2013)

Outcome of ovarian cancer after breast cancer in BRCA1 and BRCA2 mutation carriers
por: Zaaijer, Leendert H, et al.
Publicado: (2016)

Lifestyle Risk Factors for Breast Cancer in BRCA1/2-Mutation Carriers Around Childbearing Age
por: van Erkelens, A., et al.
Publicado: (2016)

Mutation Analysis of BRCA1 and BRCA2 in Italian Hereditary and Sporadic Forms of Breast and Ovarian Cancers: Tumor Genotype-Phenotype Correlation in Breast Cancer BRCA-Mutation Carriers
por: Cipollini, G., et al.
Publicado: (1999)

The added value of mammography in different age-groups of women with and without BRCA mutation screened with breast MRI
por: Vreemann, Suzan, et al.
Publicado: (2018)

Cancer risks among BRCA1 and BRCA2 mutation carriers
por: Levy-Lahad, E, et al.
Publicado: (2007)

PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer
por: Annunziata, Christina M, et al.
Publicado: (2010)

Screening and diagnostic breast MRI: how do they impact surgical treatment? Insights from the MIPA study
por: Cozzi, Andrea, et al.
Publicado: (2023)

Management of Breast Cancer in BRCA1/2 Mutation Carriers
por: Eeles, R. A., et al.
Publicado: (1999)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Management of the asymptomatic BRCA mutation carrier
por: Teller, Paige, et al.
Publicado: (2010)

Male BRCA mutation carriers: clinical characteristics and cancer spectrum
por: Ibrahim, Mohammed, et al.
Publicado: (2018)

Contribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysis
por: Phi, Xuan-Anh, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_0fdsqmb0c4ic59u8d19h43dcuu